

Report Information

More information from: <https://www.marketresearchfuture.com/reports/rheumatic-fever-market-6310>

Rheumatic Fever Market Research Report – Forecast to 2030

Report / Search Code: MRFR/Pharma/4849-HCR

Publish Date: August, 2023

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Rheumatic Fever Market Scenario

The Rheumatic Fever Market is anticipated to reach USD 1.31 Billion by 2030 at 4.60% CAGR during the forecast period 2022-2030. Rheumatic fever is an autoimmune inflammatory disease which can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group A Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves. The increasing occurrences of strep throat and growing prevalence of rheumatic heart disease are expected to be the major drivers for the growth of the market during the forecast period. Moreover, increasing government expenditure for the healthcare sector contributes to the market growth. According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally.

Despite the drivers, lack of awareness about the condition and limited healthcare facilities in emerging economies may hamper the growth of the market during the assessment period.

Segmentation

The global rheumatic fever market has been segmented into diagnosis, treatment, distribution channel, and end-user.

The market on the basis of diagnosis has been segmented into physical exam, blood test, electrocardiogram, and echocardiogram.

The market, by treatment, has been segmented into pharmacotherapy and others. The pharmacotherapy segment is further segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. Further, the anti-inflammatory medication segment has been segmented into aspirin, naproxen, and others.

The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.

On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rheumatic fever market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European rheumatic fever market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The rheumatic fever market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rheumatic fever market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Pfizer, Inc., AstraZeneca, Valeant Pharmaceuticals International, Inc., and Eli Lilly and Company are some of the key players in the global rheumatic fever market.

Regional Market Summary

Global Rheumatic Fever Market Share (%), by Region, 2017

Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)

Geographically, the Americas is anticipated to dominate the global rheumatic fever market owing to a well-developed healthcare sector, rising prevalence of cardiovascular diseases, and growing healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart diseases in the US every year. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.

Europe is expected to hold the second largest position in the global rheumatic fever market. The market growth in this region is attributed to the growing prevalence of rheumatic heart disease, availability of funds for research, and increasing healthcare expenditure.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rheumatic fever, and increasing government funding for the healthcare sector.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growing government initiatives for rheumatic heart disease. For instance, according to the RHD Global Status Report, 2015 to 2017, Egypt's Rheumatic Heart Disease (RHD) programme trained 300 cardiologists and 1,500 primary healthcare physicians in rheumatic heart disease management in 2015. However, the market in the African region is expected to propel owing to the rising prevalence of rheumatic heart disease and increasing government initiatives for the prevention of rheumatic fever.

Global Rheumatic Fever Market, by Diagnosis

- Physical Exam
- Blood Test
- Electrocardiogram
- Echocardiogram

Global Rheumatic Fever Market, by Treatment

- Pharmacotherapy
- Antibiotics
- Anti-inflammatory Medication
- Aspirin
- Naproxen
- Others
- Anticonvulsant Medication
- Others
- Others

Global Rheumatic Fever Market, by Distribution Channel

- Retail Pharmacies
- Hospital Pharmacies
- Others

Global Rheumatic Fever Market, by End-User

- Hospitals and Clinics
- Diagnostic Centers
- Others

Global Rheumatic Fever Market, by Region

- Americas
 - North America
 - US
 - Canada
 - South America
- Europe
 - Western Europe
 - Germany
 - France

- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe

- Asia-Pacific

- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

- Middle East & Africa

- Middle East
- Africa

Global Rheumatic Fever Market, by Key Players

- Bayer AG
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca
- Valeant Pharmaceuticals International, Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company

Intended Audience

- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities

Table of Content:

Contents

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers	
4.2 Restraints	
4.3 Opportunities	
4.4 Challenges	
4.5 Macroeconomic Indicators	
4.6 Technology Trends & Assessment	
Chapter 5. Market Factor Analysis	
5.1 Porter's Five Forces Analysis	
5.1.1 Bargaining Power of Suppliers	
5.1.2 Bargaining Power of Buyers	
5.1.3 Threat of New Entrants	
5.1.4 Threat of Substitutes	
5.1.5 Intensity of Rivalry	
5.2 Value Chain Analysis	
5.3 Investment Feasibility Analysis	
5.4 Pricing Analysis	
Chapter 6. Global Rheumatic Fever Market, by Diagnosis	
6.1 Introduction	
6.2 Physical Exam	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
6.3 Blood Test	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
6.4 Electrocardiogram (ECG)	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
6.5 Echocardiogram	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
Chapter 7. Global Rheumatic Fever Market, by Treatment	
7.1 Introduction	
7.2 Pharmacotherapy	
7.2.1 Antibiotics	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.2.2 Anti-Inflammatory Medication	
7.2.2.1 Aspirin	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.2.2.2 Naproxen	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.2.2.3 Others	
7.2.3 Anticonvulsant Medication	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.2.4 Others	
7.3 Others	
Chapter 8. Global Rheumatic Fever Market, by Distribution Channel	
8.1 Introduction	
8.2 Retail Pharmacies	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
8.3 Hospital Pharmacies	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
8.4 Others	
Chapter 9. Global Rheumatic Fever Market, by End-User	
9.1 Introduction	
9.2 Hospital and Clinics	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
9.3 Diagnostic Centers	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
9.4 Others	
Chapter 10. Global Rheumatic Fever Market, by Region	
10.1 Introduction	
10.2 Americas	
10.2.1 North America	
10.2.1.1 US	
10.2.1.2 Canada	
10.2.2 South America	
10.3 Europe	
10.3.1 Western Europe	
10.3.1.1 Germany	
10.3.1.2 France	
10.3.1.3 Italy	
10.3.1.4 Spain	
10.3.1.5 UK	
10.3.1.6 Rest of Western Europe	
10.3.2 Eastern Europe	
10.4 Asia-Pacific	
10.4.1 Japan	
10.4.2 China	
10.4.3 India	
10.4.4 Australia	
10.4.5 South Korea	
10.4.6 Rest of Asia-Pacific	
10.5 Middle East & Africa	
10.5.1 Middle East	
10.5.2 Africa	

Chapter 11. Company Landscape

- 11.1 Introduction
- 11.2 Market Share Analysis
- 11.3 Key Development & Strategies

Chapter 12. Company Profiles

- 12.1 Bayer AG
 - 12.1.1 Company Overview
 - 12.1.2 Product Overview
 - 12.1.3 Financials Overview
 - 12.1.4 Key Developments
 - 12.1.5 SWOT Analysis
- 12.2 Abbott Laboratories
 - 12.2.1 Company Overview
 - 12.2.2 Product Overview
 - 12.2.3 Financial Overview
 - 12.2.4 Key Developments
 - 12.2.5 SWOT Analysis
- 12.3 Johnson & Johnson Services, Inc.
 - 12.3.1 Company Overview
 - 12.3.2 Product Overview
 - 12.3.3 Financial Overview
 - 12.3.4 Key Development
 - 12.3.5 SWOT Analysis
- 12.4 F. Hoffmann-La Roche Ltd.
 - 12.4.1 Company Overview
 - 12.4.2 Product Overview
 - 12.4.3 Financial Overview
 - 12.4.4 Key Development
 - 12.4.5 SWOT Analysis
- 12.5 Novartis AG
 - 12.5.1 Company Overview
 - 12.5.2 Product Overview
 - 12.5.3 Financial overview
 - 12.5.4 Key Developments
 - 12.5.5 SWOT Analysis
- 12.6 Pfizer, Inc.
 - 12.6.1 Company Overview
 - 12.6.2 Product Overview
 - 12.6.3 Financial Overview
 - 12.6.4 Key Developments
 - 12.6.5 SWOT Analysis
- 12.7 Bristol-Myers Squibb Company
 - 12.7.1 Overview
 - 12.7.2 Product Overview
 - 12.7.3 Financial Overview
 - 12.7.4 Key Developments
 - 12.7.5 SWOT Analysis
- 12.8 AstraZeneca
 - 12.8.1 Overview
 - 12.8.2 Product Overview
 - 12.8.3 Financials
 - 12.8.4 Key Developments
 - 12.8.5 SWOT Analysis
- 12.9 Valeant Pharmaceuticals International, Inc.
 - 12.9.1 Overview
 - 12.9.2 Product Overview
 - 12.9.3 Financials
 - 12.9.4 Key Developments
 - 12.9.5 SWOT Analysis
- 12.10 Eli Lilly and Company
 - 12.10.1 Overview
 - 12.10.2 Product Overview
 - 12.10.3 Financials
 - 12.10.4 Key Developments
 - 12.10.5 SWOT Analysis

Chapter 13 MRFR Conclusion

- 13.1 Key Findings
 - 13.1.1 From CEO's Viewpoint
 - 13.1.2 Unmet Needs of the Market
- 13.2 Key Companies to Watch
- 13.3 Predictions for the Rheumatic Fever Industry

Chapter 14. Appendix

LIST OF TABLES

- Table 1 Global Rheumatic Fever Market Synopsis, 2020–2027
- Table 2 Global Rheumatic Fever Market Estimates and Forecast, 2020–2027 (USD Million)
- Table 3 Global Rheumatic Fever Market, by Region, 2020–2027 (USD Million)
- Table 4 Global Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
- Table 5 Global Rheumatic Fever Market, by Treatment, 2020–2027(USD Million)
- Table 6 Global Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
- Table 7 Global Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
- Table 8 North America: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
- Table 9 North America: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
- Table 10 North America: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
- Table 11 North America: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
- Table 12 US: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
- Table 13 US: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
- Table 14 US: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
- Table 15 US: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
- Table 16 Canada: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
- Table 17 Canada: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
- Table 18 Canada: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
- Table 19 Canada: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

Table 20 South America: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
Table 21 South America: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
Table 22 South America: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
Table 23 South America: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
Table 24 Europe: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
Table 25 Europe: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
Table 26 Europe: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
Table 27 Europe: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
Table 28 Western Europe: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
Table 29 Western Europe: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
Table 30 Western Europe: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
Table 31 Western Europe: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
Table 32 Eastern Europe: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
Table 33 Eastern Europe: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
Table 34 Eastern Europe: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
Table 35 Eastern Europe: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
Table 36 Asia-Pacific: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
Table 37 Asia-Pacific: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
Table 38 Asia-Pacific: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
Table 39 Asia-Pacific: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
Table 40 Middle East & Africa: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)
Table 41 Middle East & Africa: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)
Table 42 Middle East & Africa: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)
Table 43 Middle East & Africa: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Rheumatic Fever Market
Figure 3 Segmentation Market Dynamics for Global Rheumatic Fever Market
Figure 4 Global Rheumatic Fever Market Share, by Diagnosis, 2020
Figure 5 Global Rheumatic Fever Market Share, by Treatment, 2020
Figure 6 Global Rheumatic Fever Market Share, by Distribution Channel, 2020
Figure 7 Global Rheumatic Fever Market Share, by End-User, 2020
Figure 8 Global Rheumatic Fever Market Share, by Region, 2020
Figure 9 North America: Rheumatic Fever Market Share, by Country, 2020
Figure 10 Europe: Rheumatic Fever Market Share, by Country, 2020
Figure 11 Asia-Pacific: Rheumatic Fever Market Share, by Country, 2020
Figure 12 Middle East & Africa: Rheumatic Fever Market Share, by Country, 2020
Figure 13 Global Rheumatic Fever Market: Company Share Analysis, 2020 (%)
Figure 14 Bayer AG: Key Financials
Figure 15 Bayer AG: Segmental Revenue
Figure 16 Bayer AG: Geographical Revenue
Figure 17 Abbott Laboratories: Key Financials
Figure 18 Abbott Laboratories: Segmental Revenue
Figure 19 Abbott Laboratories: Geographical Revenue
Figure 20 Johnson & Johnson Services, Inc.: Key Financials
Figure 21 Johnson & Johnson Services, Inc.: Segmental Revenue
Figure 22 Johnson & Johnson Services, Inc.: Geographical Revenue
Figure 23 F. Hoffmann-La Roche Ltd.: Key Financials
Figure 24 F. Hoffmann-La Roche Ltd.: Segmental Revenue
Figure 25 F. Hoffmann-La Roche Ltd.: Geographical Revenue
Figure 26 Novartis AG: Key Financials
Figure 27 Novartis AG: Segmental Revenue
Figure 28 Novartis AG: Geographical Revenue
Figure 29 Pfizer, Inc.: Key Financials
Figure 30 Pfizer, Inc.: Segmental Revenue
Figure 31 Pfizer, Inc.: Geographical Revenue
Figure 32 Bristol-Myers Squibb Company: Key Financials
Figure 33 Bristol-Myers Squibb Company: Segmental Revenue
Figure 34 Bristol-Myers Squibb Company: Geographical Revenue
Figure 35 AstraZeneca: Key Financials
Figure 36 AstraZeneca: Segmental Revenue
Figure 37 AstraZeneca: Geographical Revenue
Figure 38 Valeant Pharmaceuticals International, Inc.: Key Financials
Figure 39 Valeant Pharmaceuticals International, Inc.: Segmental Revenue
Figure 40 Valeant Pharmaceuticals International, Inc.: Geographical Revenue
Figure 41 Eli Lilly and Company: Key Financials
Figure 42 Eli Lilly and Company: Segmental Revenue
Figure 43 Eli Lilly and Company: Geographical Revenue